Please use this identifier to cite or link to this item: http://111.93.178.142:25000/jspui/handle/123456789/5534
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSimi Bridijit Gomaz-
dc.date.accessioned2026-07-02T08:37:06Z-
dc.date.available2026-07-02T08:37:06Z-
dc.date.issued2026-07-02-
dc.identifier.urihttp://111.93.178.142:25000/jspui/handle/123456789/5534-
dc.descriptionVol. 163, No. 1, p 41en_US
dc.language.isoenen_US
dc.subjectAntihypertensive agentsen_US
dc.subjectDiabetes mellitusen_US
dc.subjectEndothelin - 1en_US
dc.subjectHypertensionen_US
dc.subjectInsulin resiatanceen_US
dc.titleTelmisartan vs. other antihypartensives on cardioetabolic and vascular outcomes in diabetic hypertension : A randomised trialen_US
dc.typeOtheren_US
Appears in Collections:Vol. 163, No. 1, 2026

Files in This Item:
File Description SizeFormat 
1.jpegVol. 163, No. 1, p 41371.11 kBJPEGView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.